Share Name Share Symbol Market Type Share ISIN Share Description
Silence Ther. LSE:SLN London Ordinary Share GB00B9GTXM62 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.875p -1.00% 86.25p 85.75p 86.75p 86.25p 86.25p 86.25p 5,000 16:29:55
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.8 -10.4 -12.1 - 45.83

Silence Therapeutics (SLN) Latest News

More Silence Therapeutics News
Silence Therapeutics Takeover Rumours

Silence Therapeutics (SLN) Share Charts

1 Year Silence Therapeutics Chart

1 Year Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

1 Month Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Intraday Silence Therapeutics Chart

Silence Therapeutics (SLN) Discussions and Chat

Silence Therapeutics Forums and Chat

Date Time Title Posts
21/4/201709:26Silence Therapeutics (the old SR Pharma)47,202.00
06/10/201609:04Gower Productions Presents ....."PREDICTA BID"52.00
29/5/201310:32Silence Therapeutics - news and views1,412.00
15/2/201308:57SLN - I see no ships, but I do see 10p looming, ahoy!368.00

Add a New Thread

Silence Therapeutics (SLN) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Silence Therapeutics trades in real-time

Silence Therapeutics (SLN) Top Chat Posts

Silence Therapeutics Daily Update: Silence Ther. is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker SLN. The last closing price for Silence Therapeutics was 87.13p.
Silence Ther. has a 4 week average price of 84p and a 12 week average price of 83.25p.
The 1 year high share price is 133.75p while the 1 year low share price is currently 83.25p.
There are currently 53,134,957 shares in issue and the average daily traded volume is 26,913 shares. The market capitalisation of Silence Ther. is £45,828,900.41.
partner: New game to play , watch the arrowhead share price !!. we appear to be in profit already (subject to currency fluctuations).
callumross: "Success in business can often hinge on opportunities taken (or indeed spurned). Yes, you require a good product, or stellar technology and, of course, decent management. But sometimes company-defining moments come down to happenstance and then having the lead-lined stomach to take the plunge. Silence Therapeutics (LON:SLN) has done just that – taken the plunge - with its US$9.6mln acquisition of an 8.4% stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR). Whether it proves to be a pivotal investment only time will tell. At the very least it looks like a well-timed transaction. Less than six months ago, when Arrowhead was valued at just shy of US$730mln, buying a shareholding of this scale was inconceivable (not mention too expensive). Then fate and poor luck intervened (for Arrowhead at least). In November it cancelled three clinical programmes for drugs designed to tackle liver disease, which caused the stock to tumble to a low of US$1.20 from that August high-point of US$8.22. Silence will have been looking on with interest – not least because the two companies are in the same area of research; they are pioneers in RNA interference (RNAi). This is the cellular process of silencing unwanted or harmful genes. The two companies also use similar delivery mechanisms – GalNAc liver technology - so there ought to be areas where the pair can collaborate. The investment starts the ball rolling in this regard – it is a conversation opener. “Any number of scenarios are possible from mergers, takeovers, cross-collaboration, licensing and at default level maybe nothing,” said Silence’s chief executive Ali Mortazavi. “We have taken a worst case that we are left we with a passive investment.” The UK firm is not alone in having taken a view on Arrowhead and backed that hunch with cold hard cash. The giant Amgen handed over an initial US$56.5mln in September to buy into RNAi therapies being developed to tackle cardiovascular disease as part of a deal worth US$617mln in staged payments. It is worth noting the equity investment at US$7.16 a share provided support for a US$500mln valuation of Arrowhead. Amgen’s interest lies with the firm’s GalNAc technology, which is unaffected by November’s decision. In fact, analysts say the platform has significant untapped potential. If the market has spotted the value still inherent in Arrowhead it has been slow to react. Silence has been far quicker to cotton on. “We are in the field and so are much more knowledgeable about what’s happening,” said Mortazavi. Technologies such as Silence’s and Arrowhead’s are undergoing clinical and preclinical assessment yet the market has assigned both discount valuations. Yet the CRISPR gene editing technology, still very much in its infancy, is receiving billions of dollars of investment cash from big pharma, while listed companies are valued between $500mln and $1bn. This is frustrating for those operating in RNAi, though it is also helped create the “extraordinary circumstances” that allowed Silence to make its move. “A lot of different stars aligned at the same time and Arrowhead fell right back into our zone,” said Mortazavi. “There wasn’t [just] one single reason we did this. At its best this could be a very, very important moment in RNA interference and the ability to actually be able to capture something. “These opportunities don’t come around very often and they may be defining moments.” One should remember Silence is first and foremost a drug development company, not an investment vehicle. “We are going down the development path ourselves. You must not forget this,” said Mortazavi. Indeed, the company continues to use its own IP and know-how to progress its liver-targeted preclinical pipeline. In addition, it is expecting pivotal clinical results from its out-licensed phase III and phase II programmes in mid-2018. The share price, up 4%, suggests the market likes the Arrowhead deal. Equally, investors don’t seem to be getting too carried away. And neither is boss Mortazavi: “We are in a place where any number of things can happen, including nothing.”
callumross: Milestone payments announced yesterday are for Quark entering Phase 3 and are IN ADDITION to the 15% which is still only a possibility depending on the outcome of phase 3 trials (the primary endpoint in the quark Phase 2 trial of 30% was achieved in a very specific subset of patients amounting to 50% of the trial participants). Surprised we didn't see a strong bounce in the share price on the announcement yesterday.
pwilk47490: Share Price slump gaining momentum! :-(
benson384: Waterloo........SLN won courtcase in Europe re-patent challenged by Alnylam (?). They thought ir worth challenging along with 3 other co's and lost. The amount of money they have and their market Cap circa $8-10bn why not just buy SLN.....? For years I have heard that SLN's tecnology/delivery is way ahead of Yanks so why not just now buy it........? Victor Kiam style !!!! Waterloo, I think you ben about a long time so your memory may pick up points I am raising and agree.........who cares all we want is a share price that now reflects the progress that has been made and the future £5 now looks cool £10 in £18 months mayeven look cheap......who knows.? No knowledge other than published and kept eye on this outfit for many years, I amy be wrong but patience is tittering on cliff of rich/reward versus sh.t...... Very open to critiscm by all, re my thoughts.
stuart14: I'm staying in. This announcement is fishy. Telling the market you are considering raising funds is a sure-fire 100% guaranteed way to generate stock selling and a lower share-price. Why do they need the shares though?
laylap: He will no doubt pause as this climbs - inevitably picking up cheaper shares as the share price falls (much as you say). So the question is why isn't he doing this in a more structured approach - i.e. taking time.....waiting the fall in share price? What's the hurry with snapping up significant numbers of shares in such a short time...........?
geoffmanana: SLN obviously has the potential to be a FTSE 250 company,but what will the share price be? I used to be a shareholder in Kenmare Resourses (KMR) a number of years ago. I bought in at 30p and they had a Market Cap of peanuts. Today they are 26p with a MC of £ other words they have diluted themselves to Hell for the benefit of the Institutions and the detriment of the Private Investor. Will SLN go the same way?........probably. Our main hope is the substantial payments SLN will receive along the way if successful. I'm holding........but watch,wait & don't be afraid to sell is my advice fwiw.
the_doctor: 'No faith in the bod here' It isnt the bod's fault There has been little they can do The issue has been that a) SLN was ramped up by IR's lot + posters on here, but failed to deliver deals b) RNAi in general has moved out of favour pending further data = SLN share price was hammered down and funds have been raised at worsening levels It is now really a case of - seeing what tech deals they can get (they've just done a small one) - keeping existing deals going (AZ renewed and Dainippon progressing) - hoping that external clinical products continue and give milestones (out of their hands) - moving Atu027 forwards and driving a deal there (scheduled for 2012) - leveraging Atu027 to push for more tech deals (as above) - keeping other tech platforms moving forward They've been doing all that. Not really a whole lot more the bod can do.
steve strang: sorry, my mistake, it means 'buoyant' wish the SLN share price was manana... ;-)
Silence Therapeutics share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20170423 15:55:07